Thomas Powles, MD, MBBS, MRCP, discusses the rationale for the BISCAY trial and what questions still need to be answered.
Combining nivolumab with the angiogenesis inhibitor tivozanib led to a high response rate and durable disease control in patients with metastatic renal cell carcinoma, a preliminary open-label study showed.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion to recommend approval of the combination of avelumab and axitinib for the frontline treatment of adult patients with advanced renal cell carcinoma.
Petros Grivas, MD, highlights the evolving role of immunotherapy in bladder cancer and ongoing research slated to further progress along.
The European Commission has approved the combination of pembrolizumab (Keytruda) and axitinib (Inlyta) for the frontline treatment of patients with advanced renal cell carcinoma.
Emerging immunotherapy combinations have offered a strong challenge to sunitinib (Sutent) in the setting of frontline advanced clear cell renal cell carcinoma.
By the end of 2018, the 57 oncology drugs launched from 2014 to 2018 had gained 89 indications across 23 cancer types. These new agents included numerous checkpoint inhibitors, which saw tremendous uptake based on their ability to dramatically improve patient outcomes.
Adding atezolizumab to platinum-based chemotherapy significantly improved progression-free survival in patients with previously untreated locally advanced or metastatic urothelial carcinoma, according to results from the phase III IMvigor130 study.
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of pembrolizumab (Keytruda) in combination with axitinib (Inlyta) for the frontline treatment of patients with advanced renal cell carcinoma.